В продолжение темы СИОЗС и мужская фертильность
В основном подобные исследования проводят для женщин. Есть всего несколько исследований посвященных мужскому фактору.
Для начала статистика:
Paternal drug use: before and during pregnancy.
Drugs such as SSRIs with possible harmful effect on the semen and/or embryo are used in 1.4% by fathers before conception.
Prescription drug use among fathers and mothers before and during pregnancy.
Among fathers, 25% used prescribed drugs during the 3 months prior to conception
Drug use among fathers around time of conception
One third of all fathers had taken up prescriptions for at least one drug in the half year before conception.
The main drugs purchased by fathers in Denmark and The Netherlands were antibiotics (14.3 and 6.3% of all fathers, respectively), analgesics (6.1 and 7.6%), antihistamines (2.0 and 2.0%) and anti-ulcer drugs (1.6 and 2.5%).
Effects of preconceptional paternal drug exposure on birth outcomes
More than 3000 of the fathers had used SSRIs during the last 3 months prior to pregnancy. A modest increased risk of pre-term birth was observed in these pregnancies (OR = 1.3, 95% CI 1.1, 1.5). There was also an increased risk of birth defects in the digestive system (OR = 1.8, 95% CI 1.2, 2.6), but no increased risk for serious birth defect or for birth defects in total.
Paternal use of antidepressants and offspring outcomes in Sweden:
Paternal antidepressant use during conception was not associated with preterm birth (adjusted odds ratio 0.91 (95% confidence interval 0.79 to 1.04)) or malformations (1.06 (0.90 to 1.26)) using logistic regression, compared with offspring born to unexposed fathers. No association was seen between antidepressant use during conception and autism (adjusted hazard ratio 1.13 (0.84 to 1.53)) or intellectual disability (0.82 (0.51 to 1.31)) using Cox regression. In children whose fathers initiated antidepressant treatment during pregnancy, results were similar for all outcomes apart from intellectual disability, which had an increased adjusted hazard ratio (1.66 (1.06 to 2.59)). Compared with the 2033 children whose fathers initiated antidepressant treatment during pregnancy, the 3983 children exposed to paternal use of antidepressants at conception had no differences in preterm birth, malformation, and autism, but a reduced risk of intellectual disability (adjusted hazard ratio 0.49 (0.26 to 0.93)).
Conclusion Paternal intake of antidepressants during the period around conception is safe with respect to the risk of the four major adverse outcomes in offspring—preterm birth, malformation, autism, or intellectual disability.
Risk of autism spectrum disorder
Compared with unexposed children, the exposed had a 1.62-fold higher risk of ASD (95% CI 1.33 to 1.96) and the risk attenuated after adjusting for potential confounders, especially fathers' psychiatric conditions (HR=1.43, 95% CI 1.18 to 1.74).
CONCLUSIONS: The mildly increased risk of ASD in the offspring associated with paternal SSRI use before conception may be attributable to paternal underlying psychiatric indications related to SSRI use or other unmeasured confounding factors.
Risk of ADHD
Compared with unexposed children, the exposed had a 26% increased risk of ADHD (HR = 1.26, 95% confidence interval [CI]: 1.06–1.51) after adjusting for potential confounders.